Ron Hunt

Ron Hunt

..................................

Managing Director

New York

Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceuticals and laboratory infrastructure companies. Ron joined the Sprout Group in January 1998, and was part of the team that spun out of Sprout in 2005 to form New Leaf. Prior to joining Sprout, Ron was a consultant with Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies) for a combined 4 years. His consulting work focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Ron held a number of sales and marketing positions for a combined 8 years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (M.B.A.) and Cornell University (B.S.).

Durata Therapeutics
IlluminOss Medical
Kalidex Pharmaceuticals
Spine Wave

Cerexa (Acquired by Forest Laboratories)
Aspreva Pharmaceuticals (NASDAQ: ASPV, Acquired by Galenica Group)
Nycomed (Acquired by Takeda Pharmaceuticals)

Phase Forward (NASDAQ: PFWD, Acquired by Oracle)
Pathology Partners (Acquired by Caris Group)
Stromedix (Acquired by Biogen Idec)


(646) 871-6400